Examkin

Question

Difficulty: HardGastroenterology and Hepatology

A 6464-year-old man with a history of type 22 diabetes mellitus and hypertension is hospitalized due to a 55-day history of high fever, right upper quadrant abdominal pain, and profound fatigue. On admission, his temperature is 39.2∘C39.2^\circ\text{C} (102.6∘F102.6^\circ\text{F}), blood pressure is 105/65 mmHg105/65\text{ mmHg}, and pulse is 112/min112/\text{min}. Physical examination is notable for hepatomegaly and localized tenderness over the right upper quadrant. Laboratory studies show a leukocyte count of 18,500/mm318,500/\text{mm}^3 with a left shift, and an alkaline phosphatase level of 450 U/L450\text{ U/L}. Contrast-enhanced abdominal CT reveals a 7-cm7\text{-cm} multiloculated fluid collection in the right hepatic lobe. A chest radiograph demonstrates a small, right-sided pleural effusion without infiltrates.

The patient undergoes successful CT-guided percutaneous drain placement for the hepatic collection, and empiric intravenous piperacillin-tazobactam and vancomycin are initiated. Three days later, he is hemodynamically stable and his fever has resolved. The right-sided pleural effusion is unchanged, and he has no respiratory distress. Abscess fluid and blood cultures both grow *Streptococcus intermedius*. Susceptibility testing shows the organism is susceptible to penicillin, ceftriaxone, and cefepime, but resistant to clindamycin.

Which of the following is the most appropriate next step in management?

  1. Discontinue current antimicrobials and initiate intravenous ceftriaxoneAnswer
  2. B
    Continue intravenous piperacillin-tazobactam and discontinue vancomycin
  3. C
    Discontinue current antimicrobials and initiate oral clindamycin
  4. D
    Remove the percutaneous hepatic drain and observe
  5. E
    Perform a diagnostic right-sided thoracentesis

Answer

Discontinue current antimicrobials and initiate intravenous ceftriaxone
The correct answer is to discontinue current antimicrobials and initiate intravenous ceftriaxone. This patient has a pyogenic liver abscess, most commonly caused by enteric gram-negative bacilli, anaerobes, or microaerophilic streptococci such as the *Streptococcus anginosus* group (including *S. intermedius*). Initial management appropriately included percutaneous drainage for source control and broad-spectrum empiric antibiotics. Once the patient achieves clinical stability and culture results identify a specific pathogen, the core principle of antimicrobial stewardship mandates de-escalating therapy to the most targeted, effective agent available. Because the isolated *S. intermedius* is susceptible to ceftriaxone, transitioning to this agent provides optimal, narrow-spectrum coverage while minimizing collateral damage to the microbiome. Ceftriaxone is highly concentrated in the biliary tract and liver, making it an excellent choice for hepatic infections.

Step-by-Step Solution

1
Assess the patient's current clinical status and the results of the diagnostic interventions.
The patient has a pyogenic liver abscess that has been source-controlled via percutaneous drainage. He is now afebrile and hemodynamically stable.
Clinical stability indicates that the initial empiric management was successful and the patient is ready for targeted definitive therapy.
2
Interpret the microbiology and susceptibility data.
Cultures grew *Streptococcus intermedius* (part of the *S. anginosus* group, notorious for abscess formation), which is susceptible to penicillin and ceftriaxone, but resistant to clindamycin.
Culture data must drive the transition from empiric to definitive antimicrobial therapy.
3
Apply principles of antimicrobial stewardship and standard guidelines for pyogenic liver abscess management.
De-escalate broad-spectrum empiric coverage to a targeted, narrow-spectrum agent (ceftriaxone).
Intravenous ceftriaxone provides excellent hepatic penetration, effective targeted coverage for the isolated organism, and allows for convenient once-daily dosing without the collateral damage of overly broad-spectrum agents.

Key Concept

The management of a pyogenic liver abscess requires percutaneous drainage for source control combined with de-escalation of empiric broad-spectrum antibiotics to targeted, narrow-spectrum therapy once culture and susceptibility data are available.
Rate this question

Topics

Gastroenterology and Hepatology

More questions from this topic